Wingspan Stent System for Intracranial Artery Stenosis

Exclusion Criteria

• •1. The target vessels was complete occlusion;
• •2. \>70% stenosis observed at the intracranial large-vessel distal to the target vessel or \>70% stenosis observed at the intracranial/extracranial large-vessel proximal to the target vessel;
• •3. Preoperative magnetic resonance showed perforating infarction in the target lesion area;
• •4. Preoperative CT showed that there was hemorrhage transformation after infarction in the target vessel area, or a history of primary cerebral hemorrhage, or a history of subarachnoid, subdural and epidural hemorrhage within 30 days before operation, or there was no treatment Chronic subdural hematoma ≥5mm;
• •5. Hospitalized surgical treatment within 30 days before operation, or planned hospitalized surgical treatment within 6 months after surgery;
• •6. CT showed Severe calcified lesions;
• •7. Previously received endovascular treatment or surgical intervention at the target vessel (except for patients with simple balloon dilatation);
• •8. Non-atherosclerosis lesions;
• •9. Patients with potential sources of cardiac embolism (such as atrial fibrillation, left ventricular thrombosis, myocardial infarction within 6 weeks);
• •10. Concomitant intracranial tumor, aneurysm or intracranial arteriovenous malformation;
• •11. Known hypersensitivity to aspirin, heparin, clopidogrel, rapamycin (sirolimus), lactic acid polymer, poly-n-butyl methacrylate, nickel-titanium alloy, or contraindications to anesthetics and contrast agents;
• •12. Hemoglobin \<100g/L, platelet count \<100\*109/L, International normalized ratio (INR) \>1.5 (irreversible) or uncorrectable hemorrhagic factors;
• •13. Uncontrollable severe hypertension (systolic blood pressure\>180 millimetres of mercury (mmHg) or diastolic blood pressure\>110mmHg);
• •14. Known liver or renal insufficiency (aspartate transaminase (ALT)\> 3x upper limit or aspartate transaminase \> 3x upper limit, Serum creatinine#250μmol/L);
• •15. Life expectancy \< 1 year;
• •16. Pregnant/lactating female patients;
• •17. Patients with cognitive impairment or mental diseases (except for those with cognitive impairment due to arterial stenosis);
• •18. Patients who were participated in other clinical trials within 3 months or participating in other clinical trials who had not yet reached the primary clinical endpoint.